Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

NCT02286921 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

222

Enrollment

OTHER

Sponsor class

Conditions

Castration Resistant Metastatic Prostate Cancer

Interventions

DRUG: Testosterone cypionate
DRUG: Enzalutamide
DRUG: Testosterone Enanthate

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]